General MedicationsORALGeneric
QTERN
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
Standard Dose
5MG;EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview QTERN is listed in Drugs@FDA under application 209091 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE Form and strength TABLET;ORAL - 5MG;EQ 5MG BASE Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2023-09-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview QTERN is listed in Drugs@FDA under application 209091 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE Form and strength TABLET;ORAL - 5MG;EQ 5MG BASE Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2023-09-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.